Day: April 29, 2025

SINGAPORE, April 29, 2025 (GLOBE NEWSWIRE) — JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a global technology company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission on April 29, 2025, Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.joyy.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company’s Investor Relations Department at joyy-ir@joyy.com. About JOYY Inc. JOYY is a leading global technology company with a mission to enrich lives through technology. With a diversified product portfolio spanning...

Award demonstrates Cycurion’s growth in public, transportation sector through comprehensive IT and cybersecurity services offering MCLEAN, Va., April 29, 2025 (GLOBE NEWSWIRE) — Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces it has been awarded a $6 million contract by a major municipal transportation agency. Under this contract, Cycurion will deliver a wide range of professional consulting services, including Audit and Cybersecurity Services, Organizational Change Management Consulting, Data Analytics, and Information Technology Services. The Scope of Work also potentially includes the integration of Cycurion’s proprietary ARx platform to further enhance operational and cybersecurity capabilities. Cycurion brings extensive transportation sector expertise,...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform. LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single, tech-enabled platform. The addition of direct access to Wegovy® through NovoCare® Pharmacy enhances LifeMD’s ability to support patients with...

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson’s Disease (PD) affects over 10 million people globally and is driven by inflammation leading to progressive neurodegeneration resulting in impaired mobility, cognitive decline, and other neurological symptoms. Abnormal alpha-synuclein accumulation/aggregation and inflammasome activation are key contributors to PD progression; targeting both may help slow or halt disease advancement. Current PD treatments address only symptoms—not the underlying disease; the global PD drug market was valued at $6.6 billion in 2024 and is projected to reach $13.3 billion by 2034 (Precedence Research).WESTON, Fla., April 29, 2025 (GLOBE NEWSWIRE) —...

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11,...

ATLANTA, April 29, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the RBC 2025 Global Healthcare Conference in New York on May 20, 2025. Management will host 1×1 investor meetings as well as a fireside chat at 11:30 a.m. Eastern Time on the same day, May 20, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call. About Aveanna Healthcare Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 34 states providing a broad range of pediatric and adult healthcare services including nursing,...